Cargando…
Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study
BACKGROUND: Type 2 diabetes is associated with both impaired insulin action at target tissues and impaired insulin secretion in pancreatic beta cells. Mitochondrial dysfunction may play a role in both insulin resistance and impaired insulin secretion. Plasma creatine has been proposed as a potential...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048485/ https://www.ncbi.nlm.nih.gov/pubmed/33348429 http://dx.doi.org/10.1111/cen.14396 |
_version_ | 1783679230908825600 |
---|---|
author | Post, Adrian Groothof, Dion Schutten, Joëlle C. Flores‐Guerrero, Jose L. Swarte, J. Casper Douwes, Rianne M. Kema, Ido P. de Boer, Rudolf A. Garcia, Erwin Connelly, Marge A. Wallimann, Theo Dullaart, Robin P. F. Franssen, Casper F. M. Bakker, Stephan J. L. |
author_facet | Post, Adrian Groothof, Dion Schutten, Joëlle C. Flores‐Guerrero, Jose L. Swarte, J. Casper Douwes, Rianne M. Kema, Ido P. de Boer, Rudolf A. Garcia, Erwin Connelly, Marge A. Wallimann, Theo Dullaart, Robin P. F. Franssen, Casper F. M. Bakker, Stephan J. L. |
author_sort | Post, Adrian |
collection | PubMed |
description | BACKGROUND: Type 2 diabetes is associated with both impaired insulin action at target tissues and impaired insulin secretion in pancreatic beta cells. Mitochondrial dysfunction may play a role in both insulin resistance and impaired insulin secretion. Plasma creatine has been proposed as a potential marker for mitochondrial dysfunction. We aimed to investigate the association between plasma creatine and incident type 2 diabetes. METHODS: We measured fasting plasma creatine concentrations by nuclear magnetic resonance spectroscopy in participants of the general population‐based PREVEND study. The study outcome was incident type 2 diabetes, defined as a fasting plasma glucose ≥7.0 mmol/L (126 mg/dl); a random sample plasma glucose ≥11.1 mmol/L (200 mg/dl); self‐report of a physician diagnosis or the use of glucose‐lowering medications based on a central pharmacy registration. Associations of plasma creatine with type 2 diabetes were quantified using Cox proportional hazards models and were adjusted for potential confounders. RESULTS: We included 4735 participants aged 52 ± 11 years, of whom 49% were male. Mean plasma creatine concentrations were 36.7 ± 17.6 µmol/L, with lower concentrations in males than in females (30.4 ± 15.1 µmol/L vs. 42.7 ± 17.7 µmol/L; p for difference <.001). During 7.3 [6.2–7.7] years of follow‐up, 235 (5.4%) participants developed type 2 diabetes. Higher plasma creatine concentrations were associated with an increased risk of incident type 2 diabetes (HR per SD change: 1.27 [95% CI: 1.11–1.44]; p < .001), independent of potential confounders. This association was strongly modified by sex (p interaction <.001). Higher plasma creatine was associated with an increased risk of incident type 2 diabetes in males (HR: 1.40 [1.17–1.67]; p < .001), but not in females (HR: 1.10 [0.90–1.34]; p = .37). CONCLUSION: Fasting plasma creatine concentrations are lower in males than in females. Higher plasma creatine is associated with an increased risk of type 2 diabetes in males. |
format | Online Article Text |
id | pubmed-8048485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80484852021-04-16 Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study Post, Adrian Groothof, Dion Schutten, Joëlle C. Flores‐Guerrero, Jose L. Swarte, J. Casper Douwes, Rianne M. Kema, Ido P. de Boer, Rudolf A. Garcia, Erwin Connelly, Marge A. Wallimann, Theo Dullaart, Robin P. F. Franssen, Casper F. M. Bakker, Stephan J. L. Clin Endocrinol (Oxf) ORIGINAL ARTICLES BACKGROUND: Type 2 diabetes is associated with both impaired insulin action at target tissues and impaired insulin secretion in pancreatic beta cells. Mitochondrial dysfunction may play a role in both insulin resistance and impaired insulin secretion. Plasma creatine has been proposed as a potential marker for mitochondrial dysfunction. We aimed to investigate the association between plasma creatine and incident type 2 diabetes. METHODS: We measured fasting plasma creatine concentrations by nuclear magnetic resonance spectroscopy in participants of the general population‐based PREVEND study. The study outcome was incident type 2 diabetes, defined as a fasting plasma glucose ≥7.0 mmol/L (126 mg/dl); a random sample plasma glucose ≥11.1 mmol/L (200 mg/dl); self‐report of a physician diagnosis or the use of glucose‐lowering medications based on a central pharmacy registration. Associations of plasma creatine with type 2 diabetes were quantified using Cox proportional hazards models and were adjusted for potential confounders. RESULTS: We included 4735 participants aged 52 ± 11 years, of whom 49% were male. Mean plasma creatine concentrations were 36.7 ± 17.6 µmol/L, with lower concentrations in males than in females (30.4 ± 15.1 µmol/L vs. 42.7 ± 17.7 µmol/L; p for difference <.001). During 7.3 [6.2–7.7] years of follow‐up, 235 (5.4%) participants developed type 2 diabetes. Higher plasma creatine concentrations were associated with an increased risk of incident type 2 diabetes (HR per SD change: 1.27 [95% CI: 1.11–1.44]; p < .001), independent of potential confounders. This association was strongly modified by sex (p interaction <.001). Higher plasma creatine was associated with an increased risk of incident type 2 diabetes in males (HR: 1.40 [1.17–1.67]; p < .001), but not in females (HR: 1.10 [0.90–1.34]; p = .37). CONCLUSION: Fasting plasma creatine concentrations are lower in males than in females. Higher plasma creatine is associated with an increased risk of type 2 diabetes in males. John Wiley and Sons Inc. 2021-01-10 2021-04 /pmc/articles/PMC8048485/ /pubmed/33348429 http://dx.doi.org/10.1111/cen.14396 Text en © 2021 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | ORIGINAL ARTICLES Post, Adrian Groothof, Dion Schutten, Joëlle C. Flores‐Guerrero, Jose L. Swarte, J. Casper Douwes, Rianne M. Kema, Ido P. de Boer, Rudolf A. Garcia, Erwin Connelly, Marge A. Wallimann, Theo Dullaart, Robin P. F. Franssen, Casper F. M. Bakker, Stephan J. L. Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study |
title | Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study |
title_full | Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study |
title_fullStr | Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study |
title_full_unstemmed | Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study |
title_short | Plasma creatine and incident type 2 diabetes in a general population‐based cohort: The PREVEND study |
title_sort | plasma creatine and incident type 2 diabetes in a general population‐based cohort: the prevend study |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048485/ https://www.ncbi.nlm.nih.gov/pubmed/33348429 http://dx.doi.org/10.1111/cen.14396 |
work_keys_str_mv | AT postadrian plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT groothofdion plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT schuttenjoellec plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT floresguerrerojosel plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT swartejcasper plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT douwesriannem plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT kemaidop plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT deboerrudolfa plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT garciaerwin plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT connellymargea plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT wallimanntheo plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT dullaartrobinpf plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT franssencasperfm plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy AT bakkerstephanjl plasmacreatineandincidenttype2diabetesinageneralpopulationbasedcohorttheprevendstudy |